Evaluation of 274 patient tumors from the TRIBUTE trial, in which patients with non-small cell lung cancer were treated with carboplatin and paclitaxel with or without erlotinib, showed a trend towards an erlotinib benefit on time to progression but not improved survival [ 26 ].
← all excerpts
A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.
1
—
—